Patients with schizophrenia (SCZ) smoke up to three times more than general people. However, there are conflicting results regarding the relationship between tobacco smoke and clinical symptom severity in SCZ. The aim of this study was to assess the impact of smoking on clinical symptoms after antipsychotic treatment in a 12-week cohort study after controlling for confounding factors. One hundred and forty-five male patients with drug-naïve first-episode (DNFE) SCZ received antipsychotic monotherapy for 12 weeks. Symptom severity was assessed at baseline and at week 12 by the Positive and Negative Syndrome Scale (PANSS). We found no differences in clinical symptoms among male smokers with SCZ compared with male nonsmokers. However, male smokers showed greater improvement in negative symptoms after 12 weeks of treatment, controlling for age, years of education, onset age, and baseline body mass index (BMI). Our study showed that after 12 weeks of treatment with antipsychotics, male smokers showed greater improvement in negative symptoms than male nonsmokers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10943037PMC
http://dx.doi.org/10.1038/s41537-024-00449-1DOI Listing

Publication Analysis

Top Keywords

male smokers
12
male patients
8
symptom severity
8
clinical symptoms
8
symptoms male
8
male nonsmokers
8
smokers greater
8
greater improvement
8
improvement negative
8
negative symptoms
8

Similar Publications

Histopathology of the small airways: Similarities and differences between ageing and COPD.

Pulmonology

December 2025

Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

Age-related lung function decline is associated with small airway closure and gas trapping. The mechanisms which cause these changes are not fully understood. It has been suggested that COPD is caused by accelerated ageing.

View Article and Find Full Text PDF

Increased plasma interleukin-1β is associated with accelerated lung function decline in non-smokers.

Pulmonology

December 2025

State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Interleukin-1β is one of the major cytokines involved in the initiation and persistence of airway inflammation in chronic obstructive pulmonary disease (COPD). However, the association between plasma interleukin-1β and lung function decline remains unclear. We aimed to explore the association between plasma interleukin-1β and lung function decline.

View Article and Find Full Text PDF

Background: The systemic immune-inflammation index (SII) is an emerging marker of inflammation, and the onset of psoriasis is associated with inflammation. The aim of our study was to investigate the potential impact of SII on the incidence rate of adult psoriasis.

Methods: We conducted a cross-sectional study based on the National Health and Nutrition Examination Survey (NHANES) 2011-2014 data sets.

View Article and Find Full Text PDF
Article Synopsis
  • Smoking is a significant public health issue in Tamil Nadu, causing preventable diseases and increasing healthcare costs, necessitating effective smoking cessation strategies in primary health care (PHC) settings.
  • The study aims to evaluate the cost-effectiveness of three proposed smoking cessation strategies against the current standard strategy, focusing on various combinations of counseling, nicotine replacement therapy, and medications for smokers aged 15 and older.
  • Results indicated that the current cessation strategy was more expensive than the proposed strategies, with two of them (PS1 and PS3) being more cost-effective, potentially leading to better resource allocation for smoking cessation efforts.
View Article and Find Full Text PDF

Introduction: Limited information exists on next-generation sequencing (NGS) success for lung tumors of 30 mm or less. We aimed to compare NGS success rates across biopsy techniques for these tumors, assess DNA sequencing quality, and verify reliability against surgical resection results.

Methods: We used data from the Initiative for Early Lung Cancer Research on Treatment study, including patients with lung tumors measuring 30 mm or less who had surgery and NGS on biopsies since 2016.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!